OnkoSightTM Next-Generation Sequencing (NGS) TUMOR MUTATION BURDEN
Tumor Mutation Burden (TMB) is the measurement of total number of somatic mutations per million bases (Mb) in a defined region of a tumor genome. TMB varies according to tumor types, as well as among patients.
In the recent years, TMB has gained importance since many clinical studies demonstrated that it is highly predictive of patient’s response to immunotherapies. These studies have identified association between high TMB and improved patient outcomes in response to anti-PD/PD-L1 and anti-CTLA-4 therapies in multiple tumor types, such as non-small cell lung cancer (NSCLC), melanoma, squamous cell carcinoma of the head and neck, small lung cancer, and urothelial carcinoma.1
OnkoSight NGS Tumor Mutation Burden Assay requires minimal sample requirement of 20ng and can interrogate ~1.7MB of the genome, thus increasing accuracy. Below is the list of genes that are included in OnkoSight NGS TMB assay.